Are Cannabinoids The Next Blockbuster Drugs? A Q&A With Jazz Pharma's CEO Bruce Cozadd
Source: Life Science Leader
By Ben Comer, Chief Editor, Life Science Leader
Jazz Pharmaceuticals’ $7.2 billion acquisition of GW Pharmaceuticals in 2021 nearly doubled the company’s headcount and placed it at the vanguard of cannabinoid companies. With the FDA approval of Epidiolex (cannabidiol) in 2018, GW Pharma became the first company to bring a prescription drug derived from marijuana plants to market.
VIEW THE MAGAZINE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Life Science Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more